Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

Erlotinib is one of the treatment choices for patients with advanced non‑small cell lung
cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Background In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in
advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

Introduction BR. 21 demonstrated significant survival benefit for non-small cell lung cancer
patients receiving erlotinib compared with placebo. We undertook to characterize, by …

Results: Patients received erlotinib in a single dose of 150 mg per day. Partial response
(PR), stable disease (SD) or progressive disease (PD) were observ-ed in 5 (9%), 33 (59%) …

7680 Background: Treatment options for previously treated NSCLC are limited, warranting
consideration of novel combinations. This study evaluated the activity and toxicity of erlotinib …

Purpose To evaluate the efficacy of erlotinib, continued after tumor progression, plus
sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung …

7504 Background: Poor performance status (PS) NSCLC is an important, under-studied
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …